CDKN2B-AS1 and esophageal squamous cell carcinoma: ANRIL is demonstrated to enhance in multiple cancers and diseases, including hepatocellular carcinoma [21], esophageal SCC [22], bladder cancer [23], prostate cancer [16], kidney malignancies [24], lung cancer [25], OSCC [12], and so forth [26].